1201633-72-8

Basic information

• Product Name: 2-BroMo-5,6-dihydro-4H-benzothiazol-7-one
• Synonyms: 2-BroMo-5,6-dihydro-4H-benzothiazol-7-one;2-BroMo-5,6-dihydrobenzo[d]thiazol-7(4H)-one
• CAS NO: 1201633-72-8
• Molecular Formula: C₇H₆BrNOS
• Molecular Weight: 232.09764
• Mol File: 1201633-72-8.mol

Chemical Properties

• Boiling Point: 335.4±11.0 °C(Predicted)
• Appearance: /
• Density: 1.763±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0?+-.0.20(Predicted)
• CAS DataBase Reference: 2-BroMo-5,6-dihydro-4H-benzothiazol-7-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BroMo-5,6-dihydro-4H-benzothiazol-7-one(1201633-72-8)
• EPA Substance Registry System: 2-BroMo-5,6-dihydro-4H-benzothiazol-7-one(1201633-72-8)

Safety Data

• Hazardous Substances Data: 1201633-72-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-5,6-dihydro-4H-benzothiazol-7-one is used as an intermediate in the synthesis of various pharmaceuticals for its potential pharmacological activities. Its unique chemical structure allows for the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, 2-Bromo-5,6-dihydro-4H-benzothiazol-7-one is utilized as an intermediate in the synthesis of agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals.
Used in Organic Synthesis:
2-Bromo-5,6-dihydro-4H-benzothiazol-7-one is used as a building block in the synthesis of other organic compounds, owing to its versatile chemical structure. This allows for the creation of new molecules with specific properties and applications in various fields.
Used in Research and Development:
2-BroMo-5,6-dihydro-4H-benzothiazol-7-one is also used in research and development for exploring its potential applications and properties. Its unique structure and pharmacological activities make it an interesting subject for scientific investigation, leading to the discovery of new uses and applications in various industries.

Upstream product

• 60060-44-8 2-bromocyclohexane-1,3-dienone 
• 932-23-0 2-chloro-cyclohexane-1,3-dione 
• 17583-10-7 2-amino-5,6-dihydrobenzo[d]thiazol-7(4H)-one 
• 540-80-7 tert.-butylnitrite 
• 805250-54-8 2-amino-5,6-dihydrobenzothiazol-7(4H)-one dihydrobromide 

Downstream Products

• 1271671-19-2 C₁₄H₁₅NOS 
• 1251924-63-6 2-(p-tolyl)-5,6-dihydrobenzo[d]thiazol-7(4H)-one 
• 1312412-56-8 2-phenylethynyl-5,6-dihydro-4H-benzothiazol-7-one 
• 1312412-60-4 (E)-2-styryl-5,6-dihydrobenzo[d]thiazol-7(4H)-one 
• 1312412-61-5 5,6-dihydro-2-(2-phenylethyl)-7(4H)-benzothiazolone 

Relevant articles and documents

Piperazinyl tetrahydrobenzothiazole oxime ether derivative and application thereof

The invention relates to a piperazinyl tetrahydrobenzothiazole oxime ether derivative shown as a general formula (I) and application of the piperazinyl tetrahydrobenzothiazole oxime ether derivative as a bactericide. The compound represents a novel bacter

BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS

Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptor

Starting from a singleton chromanone high throughput screening (HTS) hit, we describe a focused medicinal chemistry optimization effort leading to the identification of a novel series of phenoxymethyl-dihydrothiazolopyridone derivatives as selective positive allosteric modulators (PAMs) of the metabotropic glutamate 5 (mGlu5) receptor. These dihydrothiazolopyridones potentiate receptor responses in recombinant systems. In vitro and in vivo drug metabolism and pharmacokinetic (DMPK) evaluation allowed us to select compound 16a for its assessment in a preclinical animal screen of possible antipsychotic activity. 16a was able to reverse amphetamine-induced hyperlocomotion in rats in a dose-dependent manner without showing any significant motor impairment or overt neurological side effects at comparable doses. Evolution of our medicinal chemistry program, structure activity, and properties relationships (SAR and SPR) analysis as well as a detailed profile for optimized mGlu5 receptor PAM 16a are described.

BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS

The present invention relates to novel bicyclic thiazoles which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (“mGluR5”) and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which mGluR5 is involved.

3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists

The design, synthesis, and structure-activity relationship (SAR) for a series of β-substituted 3-(4-aryloxyaryl)propanoic acid GPR40 agonists is described. Systematic replacement of the pendant aryloxy group led to identification of potent GPR40 agonists. In order to identify candidates suitable for in vivo validation of the target, serum shifted potency and pharmacokinetic properties were determined for several compounds. Finally, further profiling of compound 7 is presented, including demonstration of enhanced glucose tolerance in an in vivo mouse model.

BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS

The present invention relates to novel bicyclic thiazoles of formula (I) which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 ("mGluR5") and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which mGluR5 is involved.

Azole derivatives as histamine H3 receptor antagonists, Part I: Thiazol-2-yl ethers

Most human histamine H3 receptor (hH3R) antagonists follow a general structural blueprint, containing a basic moiety linked by a spacer to a substituted core element. In this investigation the acceptance of thiazol-2-yl ether moieties in the core region is proved with some ether derivatives showing hH3R binding affinities in the nanomolar concentration range. A diversity of structural motifs is used as substituents to enhance the in vitro hH3R binding affinity.